A Multicenter, Prospective, Observational Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With Diabetic Kidney Disease and Proteinuria
Latest Information Update: 13 Jul 2023
At a glance
- Drugs Fimasartan (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms FINALE
- Sponsors Boryung Pharmaceutical
- 11 Jul 2023 Status changed from active, no longer recruiting to completed.
- 25 May 2023 Planned End Date changed from 29 Feb 2024 to 1 Jun 2023.
- 25 May 2023 Planned primary completion date changed from 31 Mar 2023 to 1 Jun 2023.